Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapyECCO '17 Barcelona
Year: 2017
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

1Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal 2Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical responseECCO '17 Barcelona
Year: 2017
Authors:

Dreesen E.*1, Van Stappen T.1, Ballet V.2, Tops S.1, Compernolle G.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

1KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium

P638: Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changesECCO '17 Barcelona
Year: 2017
Authors:

Demyanova E.1, Vakhitov T.1, Sitkin S.*1,2

1State Research Institute of Highly Pure Biopreparations, Dept. of Microbiology, St. Petersburg, Russian Federation 2North-Western State Medical University named after I.I. Mechnikov, Dept. of Internal Diseases, Gastroenterology & Dietetics, St. Petersburg, Russian Federation

P639: Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levelsECCO '17 Barcelona
Year: 2017
Authors:

Eberl A.*1,2, Huoponen S.2, Pahikkala T.3, Arkkila P.1,2, Blom M.2, Sipponen T.1,2

1Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland 2University of Helsinki, Biomedicum 2C, Helsinki, Finland 3Unversity of Turku, Department of Information Technology, Turku, Finland

P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Rowan C.R.*1, Kalei A.2, De Vries A.2, Cullen G.3,4, Ryan E.1,4, Mulcahy H.3,4, D'Haens G.5, Doherty G.A.3,4

1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland 2Sanquin Blood Supply - Diagnostic Services, Biologicals Laboratory, Amsterdam, Netherlands 3St Vincent's University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland 4University College Dublin, School of Medicine, Dublin, Ireland 5Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands

P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from KoreaECCO '17 Barcelona
Year: 2017
Authors:

Seo H.*1, Ye B.D.1,2, Lee S.-H.1, Chang K.1, Song E.M.1, Kim G.-U.1, Seo M.1, Lee H.-S.3, Hwang S.W.1,2, Park S.H.1,2, Yang D.-H.1, Kim K.-J.1,2, Byeon J.-S.1, Myung S.-J.1, Yang S.-K.1,2

1University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, South Korea 3University of Ulsan College of Medicine, Asan Medical Center, Health Screening and Promotion Center, Seoul, South Korea

P642: Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Ponte A., Pinho R., Fernandes S., Rodrigues A., Alberto L., Silva J., Rodrigues J., Sousa M., Leite S., Silva A.P., Proença L., Freitas T., Carvalho J.

Centro Hospitalar Vila Nova de Gaia/Espinho, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal

P643: Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

1Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark 2Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark

P644: Factors and salvage surgery for treatment of pouch failure after restorative proctocolectomy for ulcerative colitis – a single-institution studyECCO '17 Barcelona
Year: 2017
Authors:

Kuroki H., Sugita A., Koganei K., Tatsumi K., Futatsuki R., Obara N.

Yokohama Municipal Citizen's Hospital, Inflammatory Bowel Disease Center, Yokohama City, Japan

P645: The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospitalECCO '17 Barcelona
Year: 2017
Authors:

Whiteoak S., Johnson H., Hovell C., Weaver S., McLaughlin S.

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P646: Low FODMAPs diet as a magic bullet in reducing symptoms in different gastrointestinal diseasesECCO '17 Barcelona
Year: 2017
Authors:

Testa A., Imperatore N., Rispo A., Capone P., Rea M., Nardone O.M., Opramolla A., Tortora R., Caporaso N., Castiglione F.

University “Federico II” of Naples, Department of Clinical Medicine and Surgery, Naples, Italy

P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case seriesECCO '17 Barcelona
Year: 2017
Authors:

Zerôncio M.*1, Blake A.2, Rana-Khan Q.3, Palo W.4, Bhayat F.5

1Clínica de Oncologia de Natal, Gastroenterology, Natal, Brazil 2Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3Takeda Pharmaceutical International AG Singapore, Emerging Markets Medical Affairs, Singapore, Singapore 4Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 5Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom

P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBDECCO '17 Barcelona
Year: 2017
Authors:

Selinger C.*1, Lenti M.1, Clark T.1, Rafferty H.1, O'Connor A.1, Ahmad T.2, Hamlin J.1

1St James University Hospital, Gastroenterology, Leeds, United Kingdom 2Royal Devon & Exeter Foundation Trust, Gastroenterology, Exeter, United Kingdom

P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?ECCO '17 Barcelona
Year: 2017
Authors:

Wade K., Johnson H., Slinger K., Hovell C., Weaver S., McLaughlin S.

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P650: The prognostic impact of radical resection margins on the Recurrence of Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

van Amesfoort J.*1, Koens L.2, Bemelman W.1, Buskens C.1

1Academical Medical Centre, Surgery, Amsterdam, Netherlands 2Academical Medical Centre, Pathology, Amsterdam, Netherlands

P651: Barriers to clinical research in children with inflammatory bowel disease: the patients' perspectiveECCO '17 Barcelona
Year: 2017
Authors:

El-Matary W., Deora V.

University of Manitoba, Department of Paediatrics, Winnipeg, Canada

P652: Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)ECCO '17 Barcelona
Year: 2017
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

1ASST Rhodense, Gastroenterology Unit, Rho, Italy 2Policlinico Gemelli, Rome, Italy 3Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 4Policlinico Tor Vergata, Rome, Italy 5University of Milan, Milan, Italy 6Ospedale Mauriziano, Torino, Italy 7Ospedale Arnas Civico, Palermo, Italy 8Ospedale Cervello, Palermo, Italy 9Ospedale San Filippo Neri, Rome, Italy 10Policlinico Federico II, Naples, Italy 11University of Bologna, Bologna, Italy

P653: The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Qiu Y.*1, Zhang S.-h.2, Mao R.1, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

1The first affiliated hospital of Sun-yat Sen University, Gastroenterology, Guangzhou, China 2The first affiliated hospital of Sun-yat Sen University, Guangzhou, China

P654: Mucosal healing with a second anti-TNF-α in patients with ulcerative colitis after the failure of the previous anti-TNF-α treatmentECCO '17 Barcelona
Year: 2017
Authors:

Papa A., Pugliese D., D'Aversa F., De Vitis I., Landi R., Guidi L., Felice C., Gerardi V., Armuzzi A., Gasbarrini A., Rapaccini G.L.

Catholic University of Rome, Fondazione Policlinico Gemelli, Internal Medicine and Gastroenterology, Roma, Italy

P655: A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Derwa Y.1, Gracie D.J.*1,2, Williams C.J.1, Sood R.1,2, Mumtaz S.1, Bholah M.H.1, Hamlin P.J.1, Ford A.C.1,2

1St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom 2University of Leeds, LIBACS, Leeds, United Kingdom